ERDERA Clinical Trial Call – Call Text

Yes
Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.

Call text draft for the ERDERA Clinical Trial Call, describing governance, scope (in scope/out of scope), funding mechanism, eligibility criteria, application stages (including Stage 0 Expression of Interest and Stage 1 Short Proposal), evaluation, and annexed definitions and indicative timeline. It includes submission deadlines for Expressions of Interest (10 September 2026) and Short Proposals (29 October 2026) and provides a contact email for the Scientific Secretariat.

Version 3.2 | 10th September 2026

This call text may be subject to minor revisions. Applicants are responsible for regularly verifying that they are consulting the latest available version.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

European Rare Diseases Research Alliance (ERDERA)

Author

You might also be interested in

ERDERA 2026 Open Session

From individual cases to new treatment pathways: ERDERA Open Session focuses on ultra-rare diseases

ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.
ERDERA JTc 2027

ERDERA pre-announces 2027 Joint Transnational Call on recently identified rare diseases

The Joint Transnational Call is expected to open on 1 December 2026, with an information webinar planned for 14 December.
Training online

Information Webinar – ERDERA Joint Transnational Call 2027

December 14 @ 3:00 pm - 4:00 pm
This information webinar on the 2027 Joint Transnational Call for Proposals is scheduled for 14 December 2026.
Cover of the 16-country rare disease policy assessment, October 2026.

Reckoning With the Rare Disease Landscape. A 16 Country Policy Landscape Assessment across the Life Course.

The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.

ERDERA Search